INDICATION FOR PRIORIX
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
IMPORTANT SAFETY INFORMATION FOR PRIORIX
- Contraindications for PRIORIX are: a history of severe allergic reactions (e.g., anaphylaxis) to
- Contraindications for PRIORIX are: a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine; severe humoral or cellular (primary or acquired) immunodeficiency; and pregnancy. Pregnancy should be avoided for 1 month after vaccination
- Contraindications for PRIORIX are: a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine; severe humoral or cellular (primary or acquired) immunodeficiency; and pregnancy. Pregnancy should be avoided for 1 month after vaccination
- Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of PRIORIX
- There is a risk of febrile seizures following immunization with PRIORIX
- Thrombocytopenia and thrombocytopenic purpura have been reported following vaccination with PRIORIX
- Syncope (fainting) can occur in association with administration of injectable vaccines, including PRIORIX. Procedures should be in place to avoid injury from fainting
- The tip caps of the prefilled syringes of diluent contain natural rubber latex, which may cause allergic reactions
- Vaccination with PRIORIX may not result in protection in all vaccine recipients
- In clinical trials, the most commonly reported (≥10%) solicited adverse reactions were:
- Administration of immune globulins and other blood products concurrently with PRIORIX may interfere with the expected immune response to the vaccine
- If a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 weeks after PRIORIX to avoid false-negative results
– Age 12 through 15 months–local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%)
– Age 4 through 6 years–local: pain (41%), redness (22%) and swelling (11%); systemic: loss of appetite (21%), drowsiness (27%), and fever (24%)
– Age 7 years and older–local: pain (12%) and redness (12%)
Please see full Prescribing Information for PRIORIX.
